Skip to main content
. 2021 Feb 18;106(6):1710–1717. doi: 10.1210/clinem/dgab089

Table 2.

Multivariable Analysis: Chance of High Hematocrit for Different Determinants

Hematocrit > 0.50 L/L, crude OR (95% CI) Adjusted OR (95% CI)b Hematocrit > 0.52 L/L, crude OR (95%CI) Adjusted OR (95% CI)b
Tobacco use 2.2 (1.6–3.3) 2.0 (1.3–3.0) 3.2 (1.7–6.2) 2.7 (1.3–5.5)
Positive medical historya 2.5 (1.4–4.4) 2.0(1.1–3.8) 5.3 (2.3–12.3) 4.6 (1.9–11.2)
Age at initiation
<18 ref ref ref ref
1830 2.5 (1.4–4.4) 1.5(0.8–2.9) 3.2 (1.0–9.9) 1.9 (0.5–7.0)
3040 3.9 (2.0–7.5) 1.9 (0.9–4.0) 5.7 (1.7–19.4) 2.7 (0.6–11.3)
4050 5.9 (2.8–12.3) 3.1 (1.4–7.2) 10.3 (2.8–38.8) 4.9 (1.1–22.5)
≥50 2.6 (0.8–8.6) 1.2 (0.3–4.5) 2.9 (0.3–26.4) 1.1 (0.1–13.5)
BMI
≤18.5 0.4 (0.2–1.2) 0.6 (0.2–1.9) n/a n/a
18.5–25 ref ref ref ref
2530 3.4 (2.1–5.5) 3.0 (1.8–5.1) 5.3 (2.3–12.3) 4.3 (1.7–10.8)
≥30 3.7 (2.2–6.2) 3.1 (1.7–5.6) 6.1 (2.5–14.9) 4.6 (1.7–12.3)
Route of testosterone
T gel ref ref ref ref
Short-acting im 1.1 (0.7–1.6) 1.1 (0.7–1.7) 1.5 (0.7–3.4) 1.5 (0.6–3.7)
Long-acting im 2.9 (1.7–5.0) 3.1 (1.7–5.6) 1.0 (0.3–3.4) 1.3 (0.4–5.0)
Oral T 0.6 (0.2–1.6) 1.3 (0.4–3.7) 0.2 (0.1–2.4) 0.5 (0.1–5.6)
Unknown 1.2 (0.8–1.7) 1.9 (1.3–2.8) 1.8 (0.9–3.8) 2.9 (1.3–6.6)
Testosterone levels
010 nmol/L 0.1 (0.1–0.2) 0.1 (0.1–0.2) 0.2 (0.1–0.4) 0.1 (0.1–0.4)
1020 nmol/L ref ref ref ref
2030 nmol/L 1.3 (0.9–1.8) 1.3 (0.9–1.8) 1.3 (0.7–2.5) 1.4 (0.7–2.7)
>30 nmol/L 1.4 (1.0–1.9) 1.5 (1.1–1.8) 1.4 (0.7–2.5) 1.6 (0.8–3.0)

Abbreviations: BMI, body mass index; im, intramuscular; n/a, no data available; OR, odds ratio; T, testosterone.

a Chronic obstructive pulmonary disease/asthma, sleep apnea, chronic bronchitis, polycythemia vera

b Adjusted for all other determinants